Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
49 hedge funds and large institutions have $69.8M invested in Strongbridge Biopharma plc. in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 25 reducing their positions, and 15 closing their positions.
329% more call options, than puts
Call options by funds: $283K | Put options by funds: $66K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.62% less ownership
Funds ownership: 52.07% → 50.44% (-1.6%)
18% less funds holding
Funds holding: 60 → 49 (-11)
33% less capital invested
Capital invested by funds: $105M → $69.8M (-$35M)
68% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 25
73% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.76M |
| 2 |
Man Group
London,
United Kingdom
|
+$2.29M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$877K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$274K |
| 5 |
Jane Street
New York
|
+$89.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.21M |
| 2 |
E
Ergoteles
New York
|
-$2.19M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.2M |
| 4 |
Goldman Sachs
New York
|
-$479K |
| 5 |
CAC
Cowen and Company
New York
|
-$459K |
SBBP Hedge Fund Activity: Q3 2021 in Review
49 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q3 2021, worth a combined $69.8M — down 33% from $105M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of SBBP and 4 opened new positions — a net loss of 11 holders — while 25 trimmed existing stakes and 8 added.
The largest buyer was Stonepine Capital Management, adding an estimated $2.76M. The largest seller was OrbiMed, cutting an estimated $2.21M.
- 49 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q3 2021, down from 60 in Q2 2021.
- Funds reported $69.8M of Strongbridge Biopharma plc. stock for Q3 2021, down 33% quarter-over-quarter.
- 4 funds opened new Strongbridge Biopharma plc. positions in Q3 2021 and 15 closed out, a net change of -11 holders.
- The largest Strongbridge Biopharma plc. buyer in Q3 2021 was Stonepine Capital Management, an estimated $2.76M added.
- The largest Strongbridge Biopharma plc. seller in Q3 2021 was OrbiMed, an estimated $2.21M sold.
Based on aggregated 13F filings for Q3 2021.